Pyxis Oncology (NASDAQ:PYXS) Given "Outperform" Rating at Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS - Free Report) in a research note published on Wednesday,Benzinga reports. The brokerage currently has a $8.00 price target on the stock.

A number of other brokerages also recently issued reports on PYXS. William Blair downgraded shares of Pyxis Oncology from an "outperform" rating to a "market perform" rating in a report on Thursday, November 21st. HC Wainwright reaffirmed a "buy" rating and set a $5.00 price target on shares of Pyxis Oncology in a report on Wednesday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $9.20.

Pyxis Oncology Price Performance

PYXS stock traded up $0.09 during trading on Wednesday, hitting $1.21. 912,320 shares of the stock traded hands, compared to its average volume of 744,638. The firm's 50 day moving average is $1.33 and its two-hundred day moving average is $2.35. The stock has a market cap of $74.52 million, a price-to-earnings ratio of -1.17 and a beta of 1.11. Pyxis Oncology has a 1 year low of $0.99 and a 1 year high of $6.18.

Remove Ads

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.01. The company had revenue of $16.15 million for the quarter. As a group, analysts anticipate that Pyxis Oncology will post -1.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PYXS. LMR Partners LLP purchased a new position in shares of Pyxis Oncology in the third quarter valued at $294,000. Intech Investment Management LLC purchased a new position in shares of Pyxis Oncology in the third quarter valued at $55,000. MetLife Investment Management LLC grew its holdings in shares of Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company's stock valued at $69,000 after purchasing an additional 5,484 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Pyxis Oncology in the third quarter valued at $1,405,000. Finally, State Street Corp grew its holdings in shares of Pyxis Oncology by 28.0% in the third quarter. State Street Corp now owns 951,251 shares of the company's stock valued at $3,491,000 after purchasing an additional 208,344 shares in the last quarter. 39.09% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.